Vaccine News and Research RSS Feed - Vaccine News and Research

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
Obesity in African-American men increases prostate cancer risk

Obesity in African-American men increases prostate cancer risk

Obesity has a profoundly different effect on prostate cancer risk in African-American as compared to non-Hispanic white men. Obesity in black men substantially increases the risk of low- and high-grade prostate cancer, while obesity in white men moderately reduces the risk of low-grade cancer and only slightly increases the risk of high-grade cancer, according to the first large, prospective study to examine how race and obesity jointly affect prostate cancer risk. [More]
Researchers examine how probiotics can help improve health, prevent disease

Researchers examine how probiotics can help improve health, prevent disease

In recent years, research into the benefits of gut bacteria has exploded. Scientists across the globe are examining how these microbes can help improve health and prevent disease. [More]
SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS inks exclusive global collaboration, license agreement with TrojanTec

SELLAS Life Sciences Group, a Swiss based, development-stage biopharmaceutical company with its main focus in developing innovative products for the treatment of various indications in Oncology and the Central Nervous System, today announced that it has signed an exclusive global collaboration and license agreement with TrojanTec Ltd, a UK-based Discovery Research and Development Company affiliated with Imperial College London, UK, for the development, marketing and commercialization of the innovative and proprietary TR-1 cancer therapeutic technology and drug. [More]
STRIVE study to assess safety, efficacy of rVSV-ZEBOV candidate Ebola vaccine

STRIVE study to assess safety, efficacy of rVSV-ZEBOV candidate Ebola vaccine

The Centers for Disease Control and Prevention (CDC), in partnership with the Sierra Leone College of Medicine and Allied Health Sciences and the Sierra Leone Ministry of Health and Sanitation, is now enrolling and vaccinating volunteers for the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE). [More]
Polio immunization campaign targets 5.8 million children in Iraq

Polio immunization campaign targets 5.8 million children in Iraq

A 5-day nationwide polio immunization campaign targeting 5.8 million children under 5 years of age will begin in Iraq on Sunday 12 April. The campaign will be marked by launch events on 12 April in Baghdad, organized by the Ministry of Health, and on 13 April in Erbil organized by the Kurdistan regional Ministry of Health. [More]
Vaccinating adolescent boys against HPV could prevent oropharyngeal squamous cell cancer

Vaccinating adolescent boys against HPV could prevent oropharyngeal squamous cell cancer

A new study indicates that vaccinating 12-year-old boys against the humanpapilloma virus (HPV) may be a cost-effective strategy for preventing oropharyngeal squamous cell cancer, a cancer that starts at the back of the throat and mouth, and involves the tonsils and base of the tongue. [More]
Penn researchers receive 2015 Vaccine Industry Excellence Award

Penn researchers receive 2015 Vaccine Industry Excellence Award

The laboratory of David Weiner, PhD, a professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania, received the 2015 Vaccine Industry Excellence Award for Best Academic Research Team, at the World Vaccine Congress in Washington, DC this week. [More]
Administration of selenide protects heart tissue post cardiac arrest, shows study

Administration of selenide protects heart tissue post cardiac arrest, shows study

Damage to heart muscle from insufficient blood supply during cardiac arrest and reperfusion injury after blood flow is restored can be reduced by nearly 90 percent if selenide, a form of the essential nutrient selenium, is administered intravenously in the wake of the attack, according to a new preclinical study by researchers at Fred Hutchinson Cancer Research Center. [More]
UofL-led study focuses on flu vaccine for children with neurological disorders

UofL-led study focuses on flu vaccine for children with neurological disorders

Children who have neurological disorders such as cerebral palsy or epilepsy are no more likely to be vaccinated against influenza than youngsters without these conditions, despite the increased risk for complications from flu these children experience. [More]
UQDI reveals that Anisina drug can kill melanoma cells

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status. [More]
Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

Vanderbilt researchers join multi-center effort to accelerate development of potential Ebola therapy

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus. [More]
UTMB scientists develop quick-acting vaccine that is effective against Ebola strain

UTMB scientists develop quick-acting vaccine that is effective against Ebola strain

An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola strain that killed thousands of people in West Africa last year. [More]
Public Health Agency of Canada issues statement on measles

Public Health Agency of Canada issues statement on measles

The Public Health Agency of Canada is again reminding Canadians of the importance of ensuring their immunizations are up to date, following the confirmation of additional cases of measles in the Vancouver region. [More]
Researchers reveal molecular structure of cytotoxin from Mycoplasma pneumoniae

Researchers reveal molecular structure of cytotoxin from Mycoplasma pneumoniae

Researchers from the School of Medicine at The University of Texas Health Science Center at San Antonio today revealed the molecular structure of the cytotoxin from Mycoplasma pneumoniae, a widespread, highly contagious bacterium that infects the lungs. [More]
New study could point to potential ways to address defects in learning, memory

New study could point to potential ways to address defects in learning, memory

Just as some people seem built to run marathons and have an easier time going for miles without tiring, others are born with a knack for memorizing things, from times tables to trivia facts. These two skills—running and memorizing—are not so different as it turns out. [More]
Study: Gene variant, urban environment increase risk of severe disease in children infected with RSV

Study: Gene variant, urban environment increase risk of severe disease in children infected with RSV

A particular genetic mutation combined with an urban environment increases the risk of severe disease in children infected with respiratory syncytial virus (RSV), an international team of investigators has found. [More]
Quebec Breast Cancer Foundation announces $4.5M investment for 9 homegrown researchers

Quebec Breast Cancer Foundation announces $4.5M investment for 9 homegrown researchers

The Quebec Breast Cancer Foundation is proud to announce a $4.5 million investment for 9 homegrown researchers, thanks to the continued generosity of its donors and partners. [More]
MabVax closes $11.6 million in private placement

MabVax closes $11.6 million in private placement

MabVax Therapeutics Holdings, Inc., a clinical-stage cancer immunotherapy company, is pleased to announce that it has closed on gross proceeds of approximately $11.6 million in a private placement (the "Private Placement") led by OPKO Health, Inc. and Dr. Phillip Frost, CEO and Chairman of OPKO Health. [More]
Personalized cancer vaccines can be used to marshal powerful immune response

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. [More]
CHLA infectious diseases specialist discusses how parents can prevent measles outbreak

CHLA infectious diseases specialist discusses how parents can prevent measles outbreak

Since December, there have been more than 130 confirmed cases of measles in the state of California, most of them connected to an outbreak that originated in a Southern California amusement park. Many of the infected persons were not vaccinated against the extremely contagious virus, which manifests itself through rash, fever and coughing. [More]
Advertisement
Advertisement